Clinical Trial Update: Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid [Phase 2]

View source ↗

Summary

A Phase 2 clinical evaluation of alvimopan (SB767905) for opioid-induced constipation in cancer patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Alvimopan (alvimopan)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Cancer, Constipation | Phase 2 | Status: TERMINATED